GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InMed Pharmaceuticals Inc (TSX:IN) » Definitions » Equity-to-Asset

InMed Pharmaceuticals (TSX:IN) Equity-to-Asset : 0.84 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is InMed Pharmaceuticals Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. InMed Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was C$17.14 Mil. InMed Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was C$20.47 Mil. Therefore, InMed Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.84.

The historical rank and industry rank for InMed Pharmaceuticals's Equity-to-Asset or its related term are showing as below:

TSX:IN' s Equity-to-Asset Range Over the Past 10 Years
Min: -29.67   Med: 0.84   Max: 0.98
Current: 0.84

During the past 13 years, the highest Equity to Asset Ratio of InMed Pharmaceuticals was 0.98. The lowest was -29.67. And the median was 0.84.

TSX:IN's Equity-to-Asset is ranked better than
73.95% of 1566 companies
in the Biotechnology industry
Industry Median: 0.66 vs TSX:IN: 0.84

InMed Pharmaceuticals Equity-to-Asset Historical Data

The historical data trend for InMed Pharmaceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InMed Pharmaceuticals Equity-to-Asset Chart

InMed Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.92 0.75 0.75 0.71 0.86

InMed Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.85 0.84 0.86 0.88 0.84

Competitive Comparison of InMed Pharmaceuticals's Equity-to-Asset

For the Biotechnology subindustry, InMed Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InMed Pharmaceuticals's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InMed Pharmaceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where InMed Pharmaceuticals's Equity-to-Asset falls into.



InMed Pharmaceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

InMed Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Equity to Asset (A: Jun. 2023 )=Total Stockholders Equity/Total Assets
=16.063/18.741
=0.86

InMed Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=17.135/20.466
=0.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InMed Pharmaceuticals  (TSX:IN) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


InMed Pharmaceuticals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of InMed Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


InMed Pharmaceuticals (TSX:IN) Business Description

Traded in Other Exchanges
Address
815 West Hastings Street, Suite 310, Vancouver, BC, CAN, V6C 1B4
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.

InMed Pharmaceuticals (TSX:IN) Headlines

No Headlines